Raina Ernstoff, MD
Neurology · Royal Oak, MINPI 1346212214
Payments from drug & device makers
Across 317 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$655
- Argenx US, Inc.$474
- MDD US Operations, LLC$392
- Biogen$380
- Novartis$302
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$210%
- Food & beverage$5,60198%
- Education$1112%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 86 | $1,381 |
| Teva Pharmaceuticals USA, Inc. | 38 | $655 |
| Argenx US, Inc. | 26 | $474 |
| MDD US Operations, LLC | 20 | $392 |
| Biogen | 20 | $380 |
| Novartis | 20 | $302 |
| Kyowa Kirin, Inc. | 8 | $264 |
| AbbVie(2 entities) | 13 | $233 |
| EMD Serono, Inc. | 12 | $211 |
| Amgen | 10 | $148 |
| Amneal Pharmaceuticals LLC | 7 | $144 |
| E.r. Squibb & Sons, L.L.C. | 6 | $126 |
| AstraZeneca | 5 | $111 |
| Bristol Myers Squibb | 4 | $83 |
| Pfizer | 4 | $83 |
| Genentech USA, Inc. | 5 | $76 |
| Acorda Therapeutics, Inc | 3 | $66 |
| Catalyst Pharmaceuticals, Inc. | 2 | $62 |
| Neurocrine Biosciences, Inc. | 3 | $56 |
| CSL Behring | 3 | $55 |
| Validus Pharmaceuticals LLC | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Johnson & Johnson | 1 | $40 |
| Eisai Inc. | 2 | $39 |
| Sanofi | 2 | $35 |
| Vertical Pharmaceuticals, LLC | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| GE HealthCare | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| SK Life Science, Inc. | 1 | $13 |
| Promius Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NOURIANZ$127
How this compares
$5,733 in reported general payments places this provider in the 65th percentile of 652 neurology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 13 | $106,831 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $100,985 |
| RytaryCarbidopa/Levodopa | 28 | $29,652 |
| GlatopaGlatiramer Acetate | 11 | $29,568 |
| Pyridostigmine Bromide | 89 | $14,710 |
| EquetroCarbamazepine | 11 | $10,633 |
| Entacapone | 35 | $10,151 |
| Mycophenolate Mofetil | 22 | $6,999 |
| Lacosamide | 35 | $4,839 |
| Levetiracetam | 31 | $3,469 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 81 | $2,522 |
| Clonazepam | 36 | $1,265 |
| Memantine Hcl | 23 | $1,135 |
| AmantadineAmantadine Hcl | 20 | $1,007 |
| Omeprazole | 31 | $826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil | $144 | $51,361139 claims |
| Validus Pharmaceuticals LLCEquetro | $50 | $10,63311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 652 neurology providers in Michigan.
Other neurology in Royal Oak
- Aaron EllenbogenFarmington Hills$14.5M
- Martin BelkinFarmington Hills$5.8M
- Evanthia BernitsasDetroit$4.8M
- Yang Mao DraayerFarmington Hills$4.2M
- Mirela CerghetDetroit$3.8M
- Peter le WittWest Bloomfield$3.2M
- Judith HeidebrinkAnn Arbor$2.2M
- Denise LeungAnn Arbor$2M
- Rany AburashedOwosso$1.9M
- Jeanie CoteOwosso$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.